Results 41 to 50 of about 276,902 (250)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

Frontiers in Pharmacology, 2021
Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab ...
Giulia Scioscia, Giulia Scioscia, Giovanna Elisiana Carpagnano, Carla Maria Irene Quarato, Carla Maria Irene Quarato, Donato Lacedonia, Donato Lacedonia, Sonia Santamaria, Sonia Santamaria, Piera Soccio, Annarita Depalo, Paolo Fuso, Paolo Fuso, Maria Pia Foschino Barbaro, Maria Pia Foschino Barbaro   +14 more
doaj   +1 more source

Targeting eosinophils: severe asthma and beyond

Drugs in Context, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma ...
Marco, Francesco, Lucia, Gianenrico
doaj   +1 more source

Update on Reslizumab for Eosinophilic Asthma

, 2021
Introduction Patients with severe eosinophilic asthma have an unmet need for novel and efficacious treatments. Reslizumab is one of three monoclonal antibodies targeting the interleukin-5 (IL5) pathway and has been found in phase 3b clinical trials to ...
Israel, Elliot, Cardet, Juan Carlos
core   +1 more source

Successful treatment with dupilumab for mucus plugs in severe asthma

Respirology Case Reports, 2023
A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used a high dose of inhaled corticosteroids and a long‐acting beta‐2 agonists. Chest
Moriyasu Anai, Chieko Yoshida, Hiroki Izumi, Kei Muramoto, Koichi Saruwatari, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakagami   +7 more
doaj   +1 more source

Lactiplantibacillus Plantarum GUANKE Alleviates Allergic Asthma by Restricting Monocyte‐to‐DC Differentiation Via Microbiota‐Associated IAA

Advanced Science, EarlyView.
Lactiplantibacillus plantarum GUANKE remodels the indigenous gut microbiota and is associated with microbiota‐dependent restoration of circulating IAA. IAA treatment attenuates JAK3‐STAT3 and Jag1‐Notch4‐Hey1 signaling and reduces CX3CR1+Ly6C− monocytic precursor generation and pulmonary CD11b+ DC accumulation, together with reduced Th2 inflammation ...
Yujia He, Jielan Mi, Zhiping Zhao, Xiao Zhang, Zhihan Yang, Kun Yue, Yuanming Huang, Liqiong Song, Xiaoting Wen, Jianguo Xu, Zhihong Ren   +10 more
wiley   +1 more source

Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes

Clinical and Translational Allergy
Background As a surrogate for eosinophilic activation, eosinophil‐derived neurotoxin (EDN) is a potential clinical biomarker. However, EDN levels and discriminatory ability in different asthma phenotypes are unknown.
Saliha Selin Özuygur Ermis, Carina Malmhäll, Magnus P. Borres, Robert Movérare, Daniil Lisik, Reshed Abohalaka, Selin Ercan, Susanne Schmeisser, Rani Basna, Roxana Mincheva, Göran Wennergren, Jan Lötvall, Linda Ekerljung, Madeleine Rådinger, Hannu Kankaanranta, Bright I. Nwaru   +15 more
doaj   +1 more source

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy

Pharmaceutics, 2023
The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis.
Diego Bagnasco, Edoardo Vincenzo Savarino, Mona-Rita Yacoub, Fulvio Braido, Maria Giulia Candeliere, Edoardo Giannini, Giovanni Passalacqua, Elisa Marabotto   +7 more
doaj   +1 more source

Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges

Advanced Science, EarlyView.
Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib, Shan Jiang, Joyce ZX Lee, CW Lim, HL Yeung, Nicki YH Leung, Patrick SC Leung, Ting F Leung, Christine YY Wai   +8 more
wiley   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source

Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel, Narin N. Carmel, Shaun Edalati, Hen Chaushu, Forsan Jahshan, Yaniv Hadi, Timur Pestrikov, Leonor Leider Trejo, Nidal Muhanna, Avraham Abergel   +9 more
wiley   +1 more source